For many pharmaceutical companies, receiving a Marketing Authorisation (MA) marks a major milestone – the culmination of years of development and regulatory effort. However, approval is not the end of the journey. In reality, it signals the start of an equally critical phase: ongoing licence maintenance.

Without the right oversight, organisations risk “registration drift”, a gradual misalignment that can expose both compliance and patient safety to unnecessary risk.

What is Registration Drift?

A term coined by Woodley BioReg’s regulatory specialists, registration drift describes the point at which a product begins to diverge from the conditions set out in its approved licence. This can relate to changes in manufacturing processes, controls, suppliers or documentation that are not fully reflected in the Marketing Authorisation.

Individually, these changes may seem minor. But over time, they can accumulate, creating a growing gap between what is approved and what is happening in practice.

Left unchecked, this can lead to:

  • Increased regulatory scrutiny
  • Risk of product suspension
  • Financial and operational impact
  • Potential implications for patient safety

Why Does It Happen?

In most cases, registration drift is not the result of deliberate non-compliance. It arises from the complexity of managing products in a constantly evolving regulatory and operational environment.

Common contributing factors include:

  • Inadequate lifecycle management following approval
  • Gaps in change control and variation processes
  • Evolving regulatory expectations
  • Internal resource constraints

Having reviewed more than 10,000 Marketing Authorisations, we’ve seen how quickly these pressures can lead to misalignment; particularly where post-approval strategy is not clearly defined.

Managing Registration Drift Across the Lifecycle

Addressing registration drift requires a joined-up approach across regulatory, quality and safety functions.

From a regulatory perspective, maintaining alignment means ensuring that all changes – whether driven by legislation or manufacturing updates – are captured, assessed and submitted through the appropriate variation pathways.

Equally, robust quality systems are essential. Effective management of change controls, deviations, investigations and audits helps ensure that day-to-day operations remain consistent with the approved licence.

Pharmacovigilance must also evolve alongside the product. As Marketing Authorisations change, safety systems need to remain aligned to ensure ongoing compliance and patient protection.

Overlaying all of this is the need for a dynamic regulatory strategy. As global requirements continue to shift, organisations must regularly review and adapt their approach to remain compliant while supporting growth.

From Risk to Opportunity

While registration drift presents a clear compliance risk, it also offers an opportunity.

Organisations that take a proactive approach to licence maintenance, through regular gap analysis and risk-based remediation, are better positioned to:

  • Reduce regulatory exposure
  • Streamline operations
  • Maintain consistent product quality
  • Support long-term market access

A Continuous Commitment

Maintaining a Marketing Authorisation is an ongoing, resource-intensive process and one that is often underestimated. But with increasing regulatory scrutiny and evolving global requirements, ensuring alignment between licence and practice has never been more important.

At Woodley BioReg, we work with Marketing Authorisation Holders to identify, assess and resolve registration drift – combining strategic oversight with practical implementation support.

If you are unsure whether your products remain fully aligned with their approved licences, now is the time to take a closer look.

Back to News + Insights